Skip to main content

Small Molecule Deal Benchmarks in Metabolic & Obesity

Median Upfront
$683M
Range: $375M - $979M
Total Deal Value
$3.2B
Range: $2.1B - $4.4B
Royalty Rate
14.6% - 26.7%
Tiered up to 30.7%
Dev Milestones
$460M
Range: $311M - $610M
Model Your Deal

Market Analysis

Small Molecule therapies in metabolic & obesity have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 small molecule asset in metabolic & obesity is $683M, with total deal values reaching $3.2B. Development milestones average $460M, while regulatory milestones contribute $562M.

The metabolic & obesity small molecule landscape is characterized by extremely high competitive intensity driven by the GLP-1 revolution and massive obesity market opportunity. Oral formulations, dual/triple incretins, and muscle-sparing approaches command unprecedented deal valuations. The recommended deal structure allocates approximately 21% to upfront payments and 79% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for small molecule metabolic & obesity deals range from 14.6% to 26.7% at the base tier, with tiered escalation reaching 18.6%-30.7% on blockbuster sales. Commercial milestones averaging $1.5B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a small molecule metabolic & obesity licensing deal?
Based on our analysis, Phase 2 small molecule licensing deals in metabolic & obesity average $683M in upfront payments, with a range of $375M to $979M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for small molecule metabolic & obesity transactions?
The median total deal value for Phase 2 small molecule assets in metabolic & obesity is $3.2B, ranging from $2.1B to $4.4B. This includes development milestones ($460M), regulatory milestones ($562M), and commercial milestones ($1.5B).
What royalty rates are standard for small molecule deals in metabolic & obesity?
Base royalty rates for small molecule metabolic & obesity transactions range from 14.6% to 26.7%, with tiered escalations reaching 18.6%-30.7% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in small molecule metabolic & obesity deals?
Small Molecule metabolic & obesity deals allocate approximately 79% of total deal value to milestones. Development milestones ($460M) make up the largest share, followed by commercial milestones ($1.5B) and regulatory milestones ($562M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

GLP-1 Agonist in Metabolic & Obesity

View

Dual Incretin in Metabolic & Obesity

View

Small Molecule in Oncology

View

Small Molecule in Neurology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included